InvestorsHub Logo
Followers 37
Posts 2259
Boards Moderated 0
Alias Born 05/10/2016

Re: Mutat post# 153691

Friday, 06/24/2022 9:05:03 AM

Friday, June 24, 2022 9:05:03 AM

Post# of 199685
As I see it, there could be multiple deals in the mix with ENZC Roche and GILD in the submerged iceburg. On a side note, GILD has worked with Roche in the past, licensing their Tamiflu to Roche. Another yet plausible deal with ENZC and Roche is with diagnostics. Their diagnostic headquarters is in Warsaw Poland and is quite impressive. "Roche creates innovative medicines and diagnostic tests that help millions of patients globally. Roche was one of the first companies to bring targeted treatments to patients. With our combined strength in pharmaceuticals and diagnostics, we are better equipped than any other company to further drive personalised healthcare. Two-thirds of our Research and Development projects are being developed with companion diagnostics. We are the world's number 1 in biotech with 17 biopharmaceuticals on the market. Over half of the compounds in our product pipeline are biopharmaceuticals, enabling us to deliver better-targeted therapies. We have been at the forefront of cancer research and treatment for over 50 years, with medicines for breast, skin, colon, ovarian, lung and numerous other cancers. We offer doctors profound information to guide treatments and to answer more patients’ questions than any other company. And our tests enable hospitals and labs to deliver that information quickly and reliably. We invest around 9 billion Swiss francs in Research and Development every year because innovation is our lifeblood. This is amongst the highest Research and Development spends in the world across all industries. We are a force of over 90,000 people working together across more than 100 countries."

https://ichgcp.net/pharma-list/office/120-roche